Tofacitinib is an oral small molecule drug that belongs to the class of Janus kinase (JAK) inhibitors. Initially approved by the FDA for the treatment of rheumatoid arthritis, it works by blocking the activity of Janus kinases, enzymes that play a crucial role in the immune response.